Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)
11:30am, Monday, 21'st Oct 2024
Novo Nordisk faces growth deceleration concerns, intensified by competitive pressures from Eli Lilly and supply chain issues. NVO can improve buying sentiments by expanding its indications beyond its
Novo Nordisk A/S - share repurchase programme
08:50am, Monday, 21'st Oct 2024
Bagsværd, Denmark, 21 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
07:31am, Monday, 21'st Oct 2024
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug ma
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
06:02am, Monday, 21'st Oct 2024
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to
Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, re
Consumer groups ask FTC to block Novo Holdings-Catalent deal
02:03pm, Thursday, 17'th Oct 2024
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catal
Ozempic, weight loss drugs found to cut substance abuse
08:54am, Thursday, 17'th Oct 2024
Weight loss drugs such as Novo Nordisk (NYSE:NVO) AS' Ozempic have been found to cut alcohol and opioid abuse, according to a new study. Published in the journal Addiction, the study showed the rate o
Novo Resources Reports 2024 Sustainability Report
10:44am, Wednesday, 16'th Oct 2024
VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise the release of its 2024 Sustainabili
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
06:15am, Wednesday, 16'th Oct 2024
These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
06:51pm, Tuesday, 15'th Oct 2024
Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Tuesday, 15'th Oct 2024
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
AZN or NVO: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 14'th Oct 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their
Novo Nordisk A/S - share repurchase programme
08:06am, Monday, 14'th Oct 2024
Bagsværd, Denmark, 14 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
Wegovy weight loss drug roll out falling short in the UK
07:52am, Monday, 14'th Oct 2024
Plans to roll out weight loss drug Wegovy through the NHS have fallen short of expectations after the treatment's approval late last year. Just 800 patients had received prescriptions of the drug by A
